Table 2 Patient and tumor characteristics
From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
Patient | Sex | Age | Primary tumor site | Previous operation | Previous chemotherapy | TNM (stage) | Duration of follow-up after diagnosis (months) | Site of metastasis | Site of tomotherapy |
|---|---|---|---|---|---|---|---|---|---|
1 | F | 53 | Head | No | No | T4N1M0(IVA) | 2.9 | Â | Pancreas |
2 | M | 61 | Body | Yes | Gemcitabine #6, Cisplatin/Capecitabine | T3N0M0 (II) | 4.9 | Â | Pancreas |
3 | M | 67 | Tail | No | No | T4N1M0(IVA) | 1.5 | Â | Pancreas |
4 | F | 76 | Body | No | Gemcitabine #5 | T4N1M0(IVA) | 7.6 | Â | Pancreas |
5 | M | 57 | Body | No | Gemcitabine/Capecitabine | T4N1M1(IVB) | 1.2 | Liver | Pancreas |
6 | F | 64 | Body, tail | No | No | T4N1M0(IVA) | 0.2 | Â | Pancreas |
7 | M | 67 | Body | No | No | T4N1M0(IVA) | 1 | Â | Pancreas |
8 | F | 71 | Body | No | Gemcitabine/Cisplatin #3 | T3N1M1(IVB) | 8 | Liver | Pancreas |
9 | M | 46 | Body, tail | No | No | T4N1M0(IVA) | 0.7 | Peritoneum | Pancreas |
10 | F | 80 | Body, tail | No | No | T3N1M0(III) | 2.3 | Â | Pancreas |
11 | F | 64 | Tail | No | Gemcitabine/Cisplatin #1 | T4N1M1(IVB) | 1.3 | Liver | Pancreas, Liver |
12 | M | 59 | Head | No | No | T3N1M1(IVB) | 1.4 | Liver | Pancreas |
13 | M | 68 | Body, tail | No | No | T4N1M1(IVB) | 0.6 | Liver | Pancreas, Liver |
14 | F | 54 | Neck, body | No | Gemcitabine/5 - FU #2 | T3N1M0(III) | 5.5 | Â | Pancreas |
15 | M | 57 | Body | Yes | Gemcitabine, Cisplatin/5 FU #6 | T4N1M1(IVB) | 5.2 | Liver | Pancreas |
16 | M | 83 | Head | No | No | T4N1M0(IVA) | 0.2 | Â | Pancreas |
17 | M | 54 | Head | No | No | T4N1M0(IVA) | 0.2 | Â | Pancreas |
18 | M | 64 | Â | Yes | Gemcitabine/xeloda #9, Irinotecan #2 | M1(IVB) | 63.3 | Lung | Lung |
19 | M | 58 | Head | No | No | T4N1M0(IVA) | 2.4 | Â | Pancreas |